Press Release   -

Investments Surge in Biotechnology Sector as Companies Accelerate Innovation Across Healthcare, Agriculture, and Industrial Applications

The global biotechnology market is undergoing a period of accelerated growth, driven by breakthroughs in biopharmaceuticals, gene and cell therapies, precision medicine, and cross-sector applications in agriculture and industrial biotech. According to a recent report by Vantage Market Research (VMR), the market was valued at USD 1.77 trillion in 2024 and is projected to reach approximately USD 7.417 trillion by 2035, reflecting a compound annual growth rate (CAGR) of approximately 13.95 % between 2025 and 2035. This press release aims to present a comprehensive overview of the biotech market, including key market trends and insights, segmentation, regional performance, major company activities, and market dynamics to support strategic decision-making across research, investment and policy arenas.

Key Takeaways

1. The biotechnology market is poised to more than quadruple in value from 2024 to 2035, signalling a robust growth trajectory
2. Growth is being fuelled by rising prevalence of chronic and rare diseases, increasing demand for biologics and advanced therapies (gene / cell therapies), and expanding applications across healthcare, agriculture and industrial biotech.
3. Technological advancements — including CRISPR/gene editing, AI-driven drug discovery, synthetic biology, and biomanufacturing innovations are transforming the industry’s underlying value chain.
4. Regions such as Asia Pacific and Latin America are emerging as high-growth zones, while North America and Europe continue to anchor market value with strong infrastructure and R&D ecosystems.
5. Key companies are increasingly pursuing strategic partnerships, acquisitions, and platform innovations to capture the next wave of biotechnology opportunities.
6. For stakeholders from venture capital, pharma, biotech, agriculture or policy, understanding segmentation (by technology/application/end-use), regional dynamics and competitive positioning is critical to harness value in the evolving biotech ecosystem.

Key Market Trends & Insights

The biotechnology market is being reshaped by multiple converging trends. First, the rise of biologics and advanced therapies (gene-therapy, cell therapy, regenerative medicine) is shifting value away from traditional small-molecule pharmaceuticals. Second, the use of artificial intelligence, big data and machine learning in drug discovery and development is accelerating product pipelines and reducing time-to-market. Third, growing cross-industry adoption for example in agriculture (genetically-modified crops, biomaterials) and industrial biotechnology (biofuels, bioplastics) is broadening the addressable market. Fourth, greater investment from governments and private sectors, coupled with favourable regulatory regimes in many geographies, is supporting scaling of biotech infrastructure and manufacturing capacity. Finally, convergence of biotech with digital/AI, synthetic biology and multi-omics tools is unlocking new opportunities but also increasing complexity and competition.

Market Size & Forecast

According to VMR, the global biotechnology market was valued at USD 1.77 trillion in 2024. Over the forecast period from 2025 to 2035, the market is projected to grow at a CAGR of approximately 13.95 %, reaching around USD 7.417 trillion by 2035. This sizable growth underscores the magnitude of opportunity across therapeutics, diagnostics, agriculture and industrial biotech segments, and places biotechnology amongst the fastest-growing sectors globally.

The biotechnology market exhibits moderate to high concentration at the upper end — major global biopharmaceutical and technology firms dominate high-value therapies, gene/cell platforms and biologics manufacturing. At the same time, the ecosystem remains fragmented and dynamic at the innovation end, with many smaller biotech start-ups, platform companies and regional players driving technology breakthroughs. Key characteristics include high R&D intensity, long development cycles, stringent regulatory requirements, scalability challenges in manufacturing biologics or cell therapies, and strong dependency on intellectual property and strategic collaborations. Moreover, cost pressures, reimbursement dynamics and supply-chain complexity are significant constraints. Biotechnology’s convergence with digital, synthetic biology and AI means that competitive advantage increasingly depends on platform capability, data access, and speed of innovation rather than purely molecule-centric approaches.

Application Insights

The biotechnology market by application includes healthcare, food & agriculture, natural resources & environment, industrial processing, and bioinformatics. The healthcare segment dominates due to its extensive use in drug discovery, gene therapy, regenerative medicine, and diagnostics. Biotechnological innovations are driving advancements in personalized medicine and biopharmaceuticals. Agricultural biotechnology is gaining momentum through genetically modified crops that improve yield and resistance. Environmental and industrial applications are expanding as sustainable biotechnological solutions address waste management, biofuel production, and pollution control.

Technology Insights

Based on technology, the market is segmented into DNA sequencing, nanobiotechnology, tissue engineering, cell-based assays, fermentation, chromatography, PCR technology, and others. DNA sequencing and PCR lead the market owing to their essential roles in genomics, precision medicine, and diagnostics. Nanobiotechnology and tissue engineering are witnessing rapid growth driven by advancements in regenerative therapies and targeted drug delivery. Meanwhile, fermentation and chromatography technologies remain critical in large-scale production and purification of biopharmaceuticals, ensuring safety, quality, and efficacy in biotechnology manufacturing processes.

Regional Insights

North America Biotechnology Market Trends

North America remains the largest regional market for biotechnology, supported by a robust R&D ecosystem, high healthcare expenditure, strong intellectual property frameworks, and a dense concentration of biotech firms and academic institutions. The U.S., in particular, acts as a global innovation hub with early adoption of advanced therapies, favourable regulatory pathways and established biomanufacturing infrastructure. Adoption of cell/gene therapies, precision medicine and biologics is high, driving significant revenue generation. For stakeholders, North America offers both scale and innovation leadership, though growth rates may moderate as pipelines mature.

Europe Biotechnology Market Trends

Europe represents a mature, innovative biotechnology market, underpinned by strong academic research, significant public-sector funding, and increasing commercialisation. Growth drivers include precision medicine initiatives, biologics expansion, and agriculture/industrial biotech push within the EU. However, challenges include regulatory heterogeneity across countries, cost containment pressures in healthcare and slower uptake of novel therapies in some markets. For biotechnology companies, Europe offers strategic access to both therapeutic and non-therapeutic biotech opportunities but demands strong local regulatory navigation and partnerships.

Asia Pacific Biotechnology Market Trends

The Asia Pacific region is set to register the fastest growth in the biotechnology market over the forecast horizon. Key drivers include large and growing patient populations, expanding healthcare infrastructure, government-backed biotech initiatives, increasing investment in R&D and manufacturing, and rising demand for biologics and biosimilars. Countries such as China, India, Japan, South Korea and Southeast Asian nations are rapidly scaling biotechnology capabilities. For players, Asia Pacific presents high-volume opportunity, though market entry may involve regulatory, reimbursement and supply-chain challenges.

Latin America Biotechnology Market Trends

Latin America is emerging as a growth frontier for biotechnology, particularly in generics/biosimilars, agricultural biotech and contract services. Healthcare investment is increasing, and governments are expanding biotech research initiatives. However, adoption of high-end therapeutics remains constrained by cost and reimbursement issues. For companies, Latin America offers potential in lower-cost manufacturing, regional partnerships and non-therapeutic biotech applications, though careful local strategy is required.

Middle East & Africa Biotechnology Market Trends

The Middle East & Africa (MEA) region presents nascent but growing opportunities in biotechnology, driven by government efforts to diversify economies via biotech, increasing healthcare spending in Gulf Cooperation Council (GCC) countries, and interest in agriculture/industrial biotech for sustainability goals. Nonetheless, adoption of advanced therapies is still limited, infrastructure gaps and regulatory variability persist. Biotechnology players must adopt tailored strategies focused on capacity-building, partnerships, training and regulatory engagement to succeed in MEA.

Top Key Players Biotechnology Market

1. Lonza
2. AstraZeneca
3. Pfizer Inc.
4. Gilead Sciences Inc.
5. F. Hoffmann-La Roche Ltd.
6. Biogen
7. CELGENE Corp.
8. Sanofi
9. Abbott
10. Novartis AG

These companies are advancing biotech capabilities through platform technologies, biologic/advanced therapy pipelines, partnerships and manufacturing/scaling investments. Their strategic moves shape competitive dynamics, investor sentiment and market access globally.

Recent Developments

1. In March 2025, AstraZeneca plc announced a major acquisition of the biotech company EsoBiotec for up to USD 1 billion to enhance its cell-therapy capabilities for cancer and autoimmune diseases.
2. In February 2024, U.S. lawmakers introduced legislation targeting foreign-biotech companies of concern, particularly Chinese firms, underscoring rising geopolitical and regulatory scrutiny in the biotechnology sector.

Market Scope

This report covers the global biotechnology market for the base year 2024 and provides a forecast through 2035. It addresses market size and forecast, segmentation by product/technology (biologics, cell/gene therapies, synthetic biology/industrial biotech), application (therapeutic, diagnostics, agricultural/industrial), end-use (pharma/biopharma, CROs/CDMOs, agriculture/industrial segments), regional analysis (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), competitive landscape (key companies, strategies) and recent strategic developments. The remit is designed to support biotech firms, investors, service providers, agriculture & industrial biotech players, policymakers and other stakeholders to navigate opportunities and risks in one of the most dynamic global markets.

Market Dynamics

Driver

A principal driver of the biotechnology market is the rising demand for biologics, advanced therapies (gene & cell therapies) and personalized medicine approaches. These offer higher efficacy, targeted treatment and are addressing unmet needs in cancer, rare diseases and chronic conditions—driving higher R&D, approvals and commercial adoption.

Restraint

A key restraint is the high cost of development, complex regulatory pathway, long time-to-market and manufacturing scalability challenges, especially for cell/gene therapies and biologics. Furthermore, reimbursement uncertainty and pricing pressures in healthcare systems globally can restrict market access and growth.

Opportunity

Significant opportunities lie in emerging markets (Asia Pacific, Latin America) with rising healthcare investment, growth in agricultural/industrial biotech, and innovation in synthetic biology, sustainable biomanufacturing and AI-driven drug discovery. Additionally, platform technologies enabling faster, lower-cost biotech development open new markets and business models.

Challenges

Challenges include intellectual-property controversies, supply-chain complexities (especially biologics raw materials or vectors for gene therapy), competition from new entrants, emerging regulatory and geopolitical risk (e.g., biotech export controls), and the need to demonstrate long-term safety and real-world value of advanced therapies.

Market Segmentation

By Product/Technology: Biologics (monoclonal antibodies, recombinant proteins) / Cell & Gene Therapies / Synthetic Biology & Industrial Biotechnology / Agricultural Biotechnology

By Application: Therapeutics (biopharmaceuticals, vaccines) / Diagnostics & Personalized Medicine / Agriculture / Industrial Biotechnology

By End-Use: Pharmaceutical & Biopharmaceutical Companies / CROs & CDMOs / Academic & Research Institutes / Agriculture & Industrial Firms

By Region: North America / Europe / Asia Pacific / Latin America / Middle East & Africa

Frequently Asked Questions

1. What was the size of the global biotechnology market in 2024?

USD 1.77 trillion.

1. What is the projected size by 2035 and the CAGR from 2025 to 2035?

The market is projected to reach around USD 7.417 trillion by 2035, growing at an estimated CAGR of 13.95 %.

1. Which region dominates the biotechnology market?

North America remains the largest region by revenue, supported by strong R&D capabilities, infrastructure and early adoption of advanced therapies.

1. Which segment is driving growth in biotechnology?

The biologics and cell/gene therapy segments are primary growth drivers, supported by increasing approvals, platform innovation and high unmet need.

1. What are key opportunities for new entrants?

Opportunities exist in platform technologies (synthetic biology, AI-driven biotech), emerging markets, agricultural/industrial biotech applications and expansion of cell/gene therapy manufacturing and services.